Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

682TiP - A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research;  Immunotherapy

Tumour Site

Presenters

Shigehiro Koganemaru

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

S. Koganemaru1, N. Yoshizuka2, S. Mizuno3, S. Hirai4, N. yamamoto5

Author affiliations

  • 1 Department Of Experimental Therapeutics, National Cancer Center Hospital East, 277-8577 - Chiba/JP
  • 2 Global Oncology R&d, Daiichi Sankyo, Inc., 07920-2311 - Basking Ridge/US
  • 3 Clinical Science, Daiichi Sankyo Co., Ltd., 134-8630 - Tokyo/JP
  • 4 Data Intelligence, Daiichi Sankyo Co., Ltd., 134-8630 - Tokyo/JP
  • 5 Department Of Experimental Therapeutics, National Cancer Center Hospital, Tokyo/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 682TiP

Background

CD147 is an immunoglobulin (Ig) superfamily membrane protein involved in key hallmarks of cancer such as cell survival, proliferation, and metastasis; it is highly expressed across a range of cancers. High CD147 expression in tumor tissue is associated with poor prognosis in multiple solid tumors, making CD147 an attractive target for novel cancer therapeutics. DS-1471, a humanized IgG4 monoclonal antibody targeting CD147, has shown preclinical antitumor activity by inhibiting complex formation between CD147 and diverse binding partners and inducing cancer cell apoptosis via upregulating a stress response. The toxicity profile and antitumor activity of DS-1471 in preclinical studies warrant clinical investigation. DS-1471 is currently being evaluated in a Phase 1 trial.

Trial design

DS-1471-079 (NCT06074705) is a Phase 1, first-in-human, open-label, multicenter, 2-part dose-escalation and -expansion study in adult patients with locally advanced or metastatic solid tumors who are unable to tolerate, whose tumors are refractory to, or who lack available standard treatment (N≈80). The study is currently recruiting. Patients must have ≥1 measurable lesion per Response Evaluation Criteria in Solid Tumors v1.1, have an Eastern Cooperative Oncology Group performance status of 0 or 1, and consent to baseline (mandatory) and on-treatment (if not contraindicated) biopsy. During dose escalation, patients will receive DS-1471 intravenously (IV) on Day 1 of each 28-day cycle. The primary objective of dose escalation is to evaluate the safety and tolerability of DS-1471 IV and determine the maximum tolerated dose and/or recommended dose for expansion (RDE). The dose-expansion part will comprise tumor-specific cohorts, determined based on dose escalation and preclinical data, in which patients receive DS-1471 IV at the RDE. The primary objective of dose expansion is to evaluate the safety of DS-1471 IV at the RDE. Safety measures for primary outcomes in this study include dose-limiting toxicities and treatment-emergent adverse events. Secondary outcome measures for both parts include best overall response, time to response, duration of response, progression-free survival, and overall survival.

Clinical trial identification

NCT06074705.

Editorial acknowledgement

Medical writing support was provided by Alexandra Mascaro, PhD, of Boldscience®, Inc.

Legal entity responsible for the study

Daiichi Sankyo.

Funding

Daiichi Sankyo.

Disclosure

S. Koganemaru: Financial Interests, Institutional, Principal Investigator: Amgen, Bristol Myers Squibb, Daiichi Sankyo, AbbVie, MSD, Incyte, Eisai Inc. N. Yoshizuka: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Stocks/Shares: Daiichi Sankyo. S. Mizuno, S. Hirai: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo. N. Yamamoto: Financial Interests, Personal, Advisory Role: Eisai, Takeda, Boehringer Ingelheim, Cmic, Chugai, Merck, Healios; Financial Interests, Personal, Invited Speaker: Chugai, Daiichi Sankyo, Eisai; Financial Interests, Institutional, Principal Investigator: Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, Ono, Janssen Pharma, MSD, Merck, GSK, Sumitomo Pharma, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, Toray, Kaken, AstraZeneca, Cmic, InventisBio, Rakuten Medical.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.